Table 5.
Comparison of adverse events between cisplatin combined with IL-2 versus cisplatin alone
| Study | Study size (N) | Myelotoxicity | Nausea/vomiting | Chest pain | Fever | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |||||||||||
| Group 1 | Group 2 | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
| Changjie H 2001 [15] | 30 | 30 | – | – | – | – | 13 | 43.3 | 0 | 0 | – | – | – | – | 10 | 33.3 | 0 | 0 |
| Xiuzhi Y 2001 [16] | 40 | 20 | 14 | 35 | 11 | 55 | 5 | 12.5 | 5 | 25 | – | – | – | – | – | – | – | – |
| Zhuo S 2004 [17] | 32 | 30 | 3 | 9.3 | 3 | 10 | 5 | 15.6 | 4 | 13.3 | – | – | – | – | – | – | – | – |
| Junyan W 2005 [18] | 48 | 34 | – | – | – | – | 12 | 25 | 8 | 23.5 | – | – | – | – | 18 | 37.5 | 11 | 32.4 |
| Haiying X 2009 [19] | 35 | 28 | 3 | 9 | 8 | 28.6 | 8 | 22.9 | 9 | 32.1 | – | – | – | – | 12 | 36.4 | 1 | 4 |
| Xiaoxia H 2009 [20] | 37 | 35 | 13 | 35.1 | 10 | 25 | 11 | 29.7 | 11 | 31.4 | – | – | – | – | 4 | 10.8 | 3 | 8.6 |
| Lizheng C 2009 [21] | 46 | 40 | – | – | – | – | – | – | – | – | 12 | 26.1 | 4 | 10 | – | – | – | – |
| Jinguang C 2009 [22] | 31 | 31 | – | – | – | – | 6 | 20 | 8 | 26 | 5 | 16 | 3 | 10 | 6 | 19 | 2 | 6 |
| Junfeng W 2010 [23] | 41 | 41 | – | – | – | – | 19 | 46.4 | 21 | 51.2 | 6 | 14.6 | 8 | 19.5 | 21 | 51.2 | 15 | 36.3 |
| Jingping Z 2010 [24] | 63 | 61 | 4 | 6.3 | 3 | 4.9 | 7 | 11.1 | 2 | 3.3 | 12 | 19.5 | 9 | 14.8 | 13 | 20.6 | 4 | 6.6 |
| Cheng X 2010 [25] | 41 | 41 | 6 | 19.4 | 8 | 25.8 | 11 | 35.5 | 7 | 26.6 | 7 | 22.6 | 4 | 12.9 | 9 | 29 | 7 | 26.6 |
| Fang S 2011 [26] | 30 | 30 | 2 | 6.6 | 3 | 10 | 4 | 13.3 | 6 | 20 | 7 | 23.3 | 5 | 16.6 | 12 | 40 | 9 | 30 |
| Yan Q 2011 [28] | 34 | 34 | 2 | 4.8 | 2 | 5.7 | 2 | 4.8 | 3 | 8.6 | 5 | 12.2 | 6 | 17.1 | 3 | 7.3 | 4 | 11.4 |
| Li J 2013 [29] | 41 | 35 | 16 | 42.1 | 13 | 37.1 | 9 | 23.7 | 8 | 22.8 | 6 | 15.8 | 4 | 11.4 | 2 | 7.1 | 3 | 8.5 |
| Lijie H 2014 [30] | 38 | 35 | 3 | 10 | 3 | 10 | 3 | 10 | 3 | 10 | 4 | 13.3 | 3 | 10 | 6 | 20 | 3 | 10 |
| Miao H 2016 [31] | 30 | 30 | 4 | 12.9 | 5 | 16.6 | 11 | 35.5 | 10 | 33.3 | 24 | 77.4 | 20 | 66.6 | – | – | – | – |
| P > 0.05 | P > 0.05 | P > 0.05 | P < 0.05 | |||||||||||||||
IL-2 interleukin-2, N, cases; Values are given as number of patients (%). Group 1 = cisplatin+IL-2; Group 2 = cisplatin alone